MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

Inclusion Criteria: * AGE: \>= 18 years and \<= 65 years * Patients with a too high transplant-related mortality (TRM) after standard transplantation (multiple myeloma, chronic lymphoid leukemia, non Hodgkin's lymphoma, myelodysplasia) * Patients with visceral contra-indication for standard transplantation: * cardiac: myocardiopathy; forced expiratory volume (FEV) \< 50%; * respiratory: abnormal carbon monoxide diffusing capacity (DLCO); * renal: creatinine clearance \< 50ml/min; * hepatic: transaminases and bilirubin \> 2 upper normal limit; * infectious: controlled fungal infection. * Karnofsky score \>= 70% * Unrelated donor HLA identical (ABC, DRB1; DQB1) * Signed informed consent Diagnosis : Chronic myelogenous leukemia (CML): * In first chronic phase, resistant to interferon with or without aracytine or refractory or resistant to Glivec * In complete response (CR) or in 2nd partial response (PR) after being in blastic phase Multiple myeloma (MM): * Relapse after autograft if the therapeutic response was evaluated to 50% Non-Hodgkin's lymphoma (NHL): * Mantle cell lymphoma after first relapse but in case of chemosensitivity ≥ 50% except for high grade lymphoma * In 2nd CR or PR chemosensitive in response ≥ 50% after autograft Chronic lymphocytic leukemia (CLL): * In 2nd CR or PR or in response ≥ 50% after autograft or in 2nd relapse after 2 lines of treatment but in case of chemosensitivity ≥ 50% Acute myeloid leukemia (AML): * In 2nd CR or in 1st CR for high risk criteria \[high risk criteria defined by: LAM 7; leukocytes \> 30,000/mm3; chromosomal abnormalities: t(6,9); abnormalities of 11q23, 17p, 11q, 20q, 21q, -5, del(5q), -7/del7q, del 9q et inv 3q\] Acute lymphoblastic leukemia (ALL): * In 2nd CR or in 1st CR if high risk criteria patients who are defined by chromosomal abnormalities t(9,22); t(1,19); t(4,11); abnormalities of 11q23 Myelodysplastic syndromes (MDS): * Patients without prior chemotherapy, with intermediate or high International Prognostic Scoring System (IPSS) score and blast cells \< 1% in bone marrow (BM) * CR or PR after chemotherapy for patients with 20 to 30% of blast cells in BM * Secondary AML patients with a response to chemotherapy (\< 30% blasts in BM and \< 5% of blast cells in blood) For all: * Adequate contraception in female patients of child bearing potential